GSK (NYSE:GSK) said a long-term followup study showed that its top-selling shingles vaccine, Shingrix, had a 79.7% efficacy rate six to 11 years after vaccination in people aged 50 and older. Results ...
Source LinkGSK (NYSE:GSK) said a long-term followup study showed that its top-selling shingles vaccine, Shingrix, had a 79.7% efficacy rate six to 11 years after vaccination in people aged 50 and older. Results ...
Source Link
Comments